Glycyrrhizin as a promising kryptonite against SARS-CoV-2 : Clinical, experimental, and theoretical evidences
© 2022 Elsevier B.V. All rights reserved..
COVID-19 is the most devastating disease in recent times affecting most people globally. The higher rate of transmissibility and mutations of SARS-CoV-2 along with the lack of potential therapeutics has made it a global crisis. Potential molecules from natural sources could be a fruitful remedy to combat COVID-19. This systematic review highlights the detailed therapeutic implication of naturally occurring glycyrrhizin and its related derivatives against COVID-19. Glycyrrhizin has already been established for blocking different biomolecular targets related to the SARS-CoV-2 replication cycle. In this article, several experimental and theoretical evidences of glycyrrhizin and related derivatives have been discussed in detail to evaluate their potential as a promising therapeutic strategy against COVID-19. Moreover, the implication of glycyrrhizin in traditional Chinese medicines for alleviating the symptoms of COVID-19 has been reviewed. The potential role of glycyrrhizin and related compounds in affecting various stages of the SARS-CoV-2 life cycle has also been discussed in detail. Derivatization of glycyrrhizin for designing potential lead compounds along with combination therapy with other anti-SARS-CoV-2 agents followed by extensive evaluation may assist in the formulation of novel anti-coronaviral therapy for better treatment to combat COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1275 |
|---|---|
| Enthalten in: |
Journal of molecular structure - 1275(2023) vom: 05. März, Seite 134642 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Banerjee, Suvankar [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 16.12.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.molstruc.2022.134642 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349801290 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349801290 | ||
| 003 | DE-627 | ||
| 005 | 20231226043505.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.molstruc.2022.134642 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1165.xml |
| 035 | |a (DE-627)NLM349801290 | ||
| 035 | |a (NLM)36467615 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Banerjee, Suvankar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Glycyrrhizin as a promising kryptonite against SARS-CoV-2 |b Clinical, experimental, and theoretical evidences |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 Elsevier B.V. All rights reserved. | ||
| 520 | |a COVID-19 is the most devastating disease in recent times affecting most people globally. The higher rate of transmissibility and mutations of SARS-CoV-2 along with the lack of potential therapeutics has made it a global crisis. Potential molecules from natural sources could be a fruitful remedy to combat COVID-19. This systematic review highlights the detailed therapeutic implication of naturally occurring glycyrrhizin and its related derivatives against COVID-19. Glycyrrhizin has already been established for blocking different biomolecular targets related to the SARS-CoV-2 replication cycle. In this article, several experimental and theoretical evidences of glycyrrhizin and related derivatives have been discussed in detail to evaluate their potential as a promising therapeutic strategy against COVID-19. Moreover, the implication of glycyrrhizin in traditional Chinese medicines for alleviating the symptoms of COVID-19 has been reviewed. The potential role of glycyrrhizin and related compounds in affecting various stages of the SARS-CoV-2 life cycle has also been discussed in detail. Derivatization of glycyrrhizin for designing potential lead compounds along with combination therapy with other anti-SARS-CoV-2 agents followed by extensive evaluation may assist in the formulation of novel anti-coronaviral therapy for better treatment to combat COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a 11β-HSD, 11β-hydroxysteroid dehydrogenase | |
| 650 | 4 | |a 3CLpro, 3-chymotrypsin-like protease | |
| 650 | 4 | |a ACE2, Angiotensin converting enzyme 2 | |
| 650 | 4 | |a ADMET, absorption distribution metabolism excretion and toxicity | |
| 650 | 4 | |a ARDS, acute respiratory distress syndrome | |
| 650 | 4 | |a CHM, Chinese herbal medicine | |
| 650 | 4 | |a CNS, central nervous system | |
| 650 | 4 | |a COVID-19, Coronavirus Disease 2019 | |
| 650 | 4 | |a CTD, C-terminal domain | |
| 650 | 4 | |a Experimental and computational evidences | |
| 650 | 4 | |a Glycyrrhizin | |
| 650 | 4 | |a HMGB1, high-mobility-group box1 | |
| 650 | 4 | |a IL, Interleukin | |
| 650 | 4 | |a INF-γ, interferon-γ | |
| 650 | 4 | |a KEGG, Kyoto Encyclopedia of Genes and Genomes | |
| 650 | 4 | |a MD, molecular dynamics | |
| 650 | 4 | |a MERS, Middle East respiratory syndrome | |
| 650 | 4 | |a MM/GBSA, Molecular Mechanics/Generalized Born Surface Area | |
| 650 | 4 | |a MM/PBSA, Molecular Mechanics Poisson-Boltzmann Surface Area | |
| 650 | 4 | |a MR, mineralocorticoid receptor | |
| 650 | 4 | |a Molecular docking interactions | |
| 650 | 4 | |a NO, nitric oxide | |
| 650 | 4 | |a NTD, N-terminal domain | |
| 650 | 4 | |a ORF, open reading frame | |
| 650 | 4 | |a PLpro, papain-like protease | |
| 650 | 4 | |a RBD, receptor-binding domain | |
| 650 | 4 | |a RMSD, Root mean square deviation | |
| 650 | 4 | |a RMSF, Root mean square fluctuation | |
| 650 | 4 | |a ROS, reactive oxygen species | |
| 650 | 4 | |a RSV, respiratory syncytial virus | |
| 650 | 4 | |a RTC, replication-transcription complex | |
| 650 | 4 | |a RdRp, RNA-dependent RNA polymerase | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a SARS-CoV-2, Severe acute respiratory syndrome coronavirus-2 | |
| 650 | 4 | |a SI, Selectivity index | |
| 650 | 4 | |a TCM, Traditional Chinese Medicine | |
| 650 | 4 | |a TLR, Toll-like receptor | |
| 650 | 4 | |a TNF-α, Tumor necrosis factor α | |
| 650 | 4 | |a Traditional Chinese medicine | |
| 650 | 4 | |a nsp, non-structural protein | |
| 700 | 1 | |a Baidya, Sandip Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Adhikari, Nilanjan |e verfasserin |4 aut | |
| 700 | 1 | |a Ghosh, Balaram |e verfasserin |4 aut | |
| 700 | 1 | |a Jha, Tarun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of molecular structure |d 1986 |g 1275(2023) vom: 05. März, Seite 134642 |w (DE-627)NLM114359369 |x 0022-2860 |7 nnns |
| 773 | 1 | 8 | |g volume:1275 |g year:2023 |g day:05 |g month:03 |g pages:134642 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.molstruc.2022.134642 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 1275 |j 2023 |b 05 |c 03 |h 134642 | ||